A Phase 1b Open-Label Study of Loncastuximab Tesirine in Combination with Other Anticancer Agents in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (LOTIS-7)
Gespeichert in:
| Veröffentlicht in: | Blood 2022-11, Vol.140 (Supplement 1), p.12079-12080 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 12080 |
|---|---|
| container_issue | Supplement 1 |
| container_start_page | 12079 |
| container_title | Blood |
| container_volume | 140 |
| creator | Hess, Brian T. Collins, Graham P. Solh, Melhem Gandhi, Mitul Wang, Ying Qin, Yajuan Yu, Eric Zinzani, Pier Luigi |
| description | |
| doi_str_mv | 10.1182/blood-2022-163277 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2022_163277</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497122070756</els_id><sourcerecordid>S0006497122070756</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1857-47ed2dae205295beb1c9b0ba9732b7900bde569d83259bb7a4e72e4f92ba37733</originalsourceid><addsrcrecordid>eNp9kMtu2zAQRYkiAeI8PiC7WSYLJiQlmRa6coy8AKEOHGct8DGK2cqkQTJt_GH9v8p21l3NXdwzmDmEXHJ2w_lE3Oo-BEsFE4LycSGk_EZGvBITyphgR2TEGBvTspb8hJym9JMxXhaiGpG_U3hZqYTANcw36GmjNPbwmj_sFkIHTfBGpfzx6dZKwxKTi84jOA-zsNbOq-yChz8ur2CeVxhh6rMzyptdfEef0677MtT2eV9cYK82CS2EOOQuKpND3MLV4nZxDXd0hn0PP4KnT8G-_xroZrverMJawVUzXz6_Unl9To471Se8-Jpn5O3hfjl7os388Xk2bajhk0rSUqIVVqFglagrjZqbWjOtalkILWvGtMVqXNvJoKLWWqoSpcCyq4VWhZRFcUb4Ya-JIaWIXbuJg4i4bTlrd97bvfd25709eB-Y7wcGh8N-O4xtMsPzBq2LaHJrg_sP_Q_Fgouk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A Phase 1b Open-Label Study of Loncastuximab Tesirine in Combination with Other Anticancer Agents in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (LOTIS-7)</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Hess, Brian T. ; Collins, Graham P. ; Solh, Melhem ; Gandhi, Mitul ; Wang, Ying ; Qin, Yajuan ; Yu, Eric ; Zinzani, Pier Luigi</creator><creatorcontrib>Hess, Brian T. ; Collins, Graham P. ; Solh, Melhem ; Gandhi, Mitul ; Wang, Ying ; Qin, Yajuan ; Yu, Eric ; Zinzani, Pier Luigi</creatorcontrib><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2022-163277</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>Blood, 2022-11, Vol.140 (Supplement 1), p.12079-12080</ispartof><rights>2022 The American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1857-47ed2dae205295beb1c9b0ba9732b7900bde569d83259bb7a4e72e4f92ba37733</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Hess, Brian T.</creatorcontrib><creatorcontrib>Collins, Graham P.</creatorcontrib><creatorcontrib>Solh, Melhem</creatorcontrib><creatorcontrib>Gandhi, Mitul</creatorcontrib><creatorcontrib>Wang, Ying</creatorcontrib><creatorcontrib>Qin, Yajuan</creatorcontrib><creatorcontrib>Yu, Eric</creatorcontrib><creatorcontrib>Zinzani, Pier Luigi</creatorcontrib><title>A Phase 1b Open-Label Study of Loncastuximab Tesirine in Combination with Other Anticancer Agents in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (LOTIS-7)</title><title>Blood</title><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kMtu2zAQRYkiAeI8PiC7WSYLJiQlmRa6coy8AKEOHGct8DGK2cqkQTJt_GH9v8p21l3NXdwzmDmEXHJ2w_lE3Oo-BEsFE4LycSGk_EZGvBITyphgR2TEGBvTspb8hJym9JMxXhaiGpG_U3hZqYTANcw36GmjNPbwmj_sFkIHTfBGpfzx6dZKwxKTi84jOA-zsNbOq-yChz8ur2CeVxhh6rMzyptdfEef0677MtT2eV9cYK82CS2EOOQuKpND3MLV4nZxDXd0hn0PP4KnT8G-_xroZrverMJawVUzXz6_Unl9To471Se8-Jpn5O3hfjl7os388Xk2bajhk0rSUqIVVqFglagrjZqbWjOtalkILWvGtMVqXNvJoKLWWqoSpcCyq4VWhZRFcUb4Ya-JIaWIXbuJg4i4bTlrd97bvfd25709eB-Y7wcGh8N-O4xtMsPzBq2LaHJrg_sP_Q_Fgouk</recordid><startdate>20221115</startdate><enddate>20221115</enddate><creator>Hess, Brian T.</creator><creator>Collins, Graham P.</creator><creator>Solh, Melhem</creator><creator>Gandhi, Mitul</creator><creator>Wang, Ying</creator><creator>Qin, Yajuan</creator><creator>Yu, Eric</creator><creator>Zinzani, Pier Luigi</creator><general>Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20221115</creationdate><title>A Phase 1b Open-Label Study of Loncastuximab Tesirine in Combination with Other Anticancer Agents in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (LOTIS-7)</title><author>Hess, Brian T. ; Collins, Graham P. ; Solh, Melhem ; Gandhi, Mitul ; Wang, Ying ; Qin, Yajuan ; Yu, Eric ; Zinzani, Pier Luigi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1857-47ed2dae205295beb1c9b0ba9732b7900bde569d83259bb7a4e72e4f92ba37733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hess, Brian T.</creatorcontrib><creatorcontrib>Collins, Graham P.</creatorcontrib><creatorcontrib>Solh, Melhem</creatorcontrib><creatorcontrib>Gandhi, Mitul</creatorcontrib><creatorcontrib>Wang, Ying</creatorcontrib><creatorcontrib>Qin, Yajuan</creatorcontrib><creatorcontrib>Yu, Eric</creatorcontrib><creatorcontrib>Zinzani, Pier Luigi</creatorcontrib><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hess, Brian T.</au><au>Collins, Graham P.</au><au>Solh, Melhem</au><au>Gandhi, Mitul</au><au>Wang, Ying</au><au>Qin, Yajuan</au><au>Yu, Eric</au><au>Zinzani, Pier Luigi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Phase 1b Open-Label Study of Loncastuximab Tesirine in Combination with Other Anticancer Agents in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (LOTIS-7)</atitle><jtitle>Blood</jtitle><date>2022-11-15</date><risdate>2022</risdate><volume>140</volume><issue>Supplement 1</issue><spage>12079</spage><epage>12080</epage><pages>12079-12080</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><pub>Elsevier Inc</pub><doi>10.1182/blood-2022-163277</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-4971 |
| ispartof | Blood, 2022-11, Vol.140 (Supplement 1), p.12079-12080 |
| issn | 0006-4971 1528-0020 |
| language | eng |
| recordid | cdi_crossref_primary_10_1182_blood_2022_163277 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| title | A Phase 1b Open-Label Study of Loncastuximab Tesirine in Combination with Other Anticancer Agents in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (LOTIS-7) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T03%3A01%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Phase%201b%20Open-Label%20Study%20of%20Loncastuximab%20Tesirine%20in%20Combination%20with%20Other%20Anticancer%20Agents%20in%20Patients%20with%20Relapsed%20or%20Refractory%20(R/R)%20B-Cell%20Non-Hodgkin%20Lymphoma%20(LOTIS-7)&rft.jtitle=Blood&rft.au=Hess,%20Brian%20T.&rft.date=2022-11-15&rft.volume=140&rft.issue=Supplement%201&rft.spage=12079&rft.epage=12080&rft.pages=12079-12080&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2022-163277&rft_dat=%3Celsevier_cross%3ES0006497122070756%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0006497122070756&rfr_iscdi=true |